NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018

Hoppe, Richard T.; Advani, Ranjana H.; Ai, Weiyun Z.; Ambinder, Richard F.; Aoun, Patricia; Armand, Philippe; Bello, Celeste M.; Benitez, Cecil M.; Bierman, Philip J.; Chen, Robert; Dabaja, Bouthaina S.; Dean, Robert M.; Forero, Andres; Gordon, Leo I.; Hernandez‐Ilizaliturri, Francisco J.; Hochberg, Ephraim P.; Huang, Jiayi; Johnston, Patrick B.; Kaminski, Mark; Kenkre, Vaishalee P.; Khan, Nadia; Maddocks, Kami J.; Maloney, David G.; Metzger, Monika L.; Moore, Joseph O.; Morgan, David S.; Moskowitz, Craig H.; Mulroney, Carolyn; Rabinovitch, Rachel; Seropian, Stuart; Tao, Randa; Winter, Jane N.; Yahalom, Joachim; Burns, Jennifer L.; Ogba, Ndiya

doi:10.6004/jnccn.2018.0013

Cited by 52 publications

(33 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Existing guidelines for HL propose distinct treatment algorithms based on risk group stratification, classifying disease as limited, intermediate and advanced, or early favorable, early unfavorable and advanced according to the European Organization for Research and Treatment of Cancer/Lymphoma Study Association (EORTC/LYSA), the German Hodgkin Study Group (GHSG) and the NCCN respectively [12,13]. These risk groups are defined by radiologic staging according to the Ann Arbor classification as well as on clinical and biological factors.…”

Section: • Staging and Risk Group Stratificationmentioning

confidence: 99%

“…A combined modality treatment approach is considered the current standard of care in resource-unlimited settings for early and intermediate stage disease. These consist in a limited number of chemotherapy cycles followed by radiotherapy [12,13]. These recommendations are based on a number of studies suggesting modestly inferior disease control in limited stage cHL treated with chemotherapy only as opposed to combined modality treatment (CMT) [39,40].…”

Section: • Early Stage Hodgkin's Lymphomamentioning

confidence: 99%

“…Whereas limiting long term treatment morbidity and mortality is a key focus of recent and future cHL treatment developments in high income countries today, health systems in many LMICs face a different reality, often struggling to provide their population access to even the most basic and potentially life-saving chemotherapy regimens. Existing evidence-based guidelines outlining current standards in HL diagnosis and treatment fail to take these discrepancies into account, assuming unlimited resources [12,13]. These guidelines are therefore inapplicable in resource-constrained settings, leaving physicians without guidance on how to optimize patient outcome with the limited resources at hand.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma

Relecom

Federico

Connors

et al. 2020

IJERPH

View full text Add to dashboard Cite

Hodgkin lymphoma is a haematological malignancy predominantly affecting young adults. Hodgkin lymphoma is a highly curable disease by current treatment standards. Latest treatment guidelines for Hodgkin lymphoma however imply access to diagnostic and treatment modalities that may not be available in settings with restricted healthcare resources. Considerable discrepancies in Hodgkin lymphoma patient survival exist, with poorer outcomes reported in resources-constrained settings. Resources-stratified guidelines for diagnosis, staging and treatment of Hodgkin lymphoma were derived in an effort to optimize patient outcome provided a given setting of available resources. These guidelines were derived based on the framework of the Breast Health Global Initiative stratifying resource levels in basic, core, advanced and maximal categories.

show abstract

Section: • Staging and Risk Group Stratificationmentioning

confidence: 99%

Section: • Early Stage Hodgkin's Lymphomamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma

Relecom

Federico

Connors

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…Modern contouring protocols recommend limited RT volumes, based on the principles of involved node radiation therapy (INRT) and Involved Site Radiation Therapy (ISRT) [12]. Volumes reduction started with the advent of CT simulation and 3D reconstruction software, which laid the groundwork for a new way of considering lymphoma radiation fields in comparison with the 2D era.…”

Section: Modern Treatment Volumes Definitionmentioning

confidence: 99%

Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin’s lymphoma involving the mediastinum

et al. 2020

View full text Add to dashboard Cite

Aim: Advances in therapy have resulted in improved cure rates and an increasing number of long-term Hodgkin's lymphoma (HL) survivors. However, radiotherapy (RT)-related late effects are still a significant issue, particularly for younger patients with mediastinal disease (secondary cancers, heart diseases). In many Centers, technological evolution has substantially changed RT planning and delivery. This consensus document aims to analyze the current knowledge of Intensity-Modulated Radiation Therapy (IMRT) and Image-Guided Radiation Therapy (IGRT) for mediastinal HL and formulate practical recommendations based on scientific evidence and expert opinions. Methods: A dedicated working group was set up within the Fondazione Italiana Linfomi (FIL) Radiotherapy Committee in May 2018. After a first meeting, the group adopted a dedicated platform to share retrieved articles and other material. Two group coordinators redacted a first document draft, that was further discussed and finalized in two subsequent meetings. Topics of interest were: 1) Published data comparing 3D-conformal radiotherapy (3D-CRT) and IMRT 2) dose objectives for the organs at risk 3) IGRT protocols and motion management.

show abstract

“…Так, согласно российским клиническим рекомендациям (табл. 1) по диагностике и лечению злокачественных лимфопролиферативных за-болеваний (2016), а также рекомендациям EBMT (2010), ASBMT (American Society of Bone Marrow Transplantation, 2015) и NCCN (National Comprehensive Cancer Network, 2017), стандартом для выполнения процедуры является химиочувствительный рецидив [1,[8][9][10].…”

Section: Introductionunclassified

Outcome of Classical Hodgkin’s Lymphoma Treatment Based on HighDose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation: The Experience in the NI Pirogov Russian National Medical Center of Surgery

Мочкин

Саржевский

Dubinina

et al. 2018

Клиническая онкогематология

View full text Add to dashboard Cite

Aim. To estimate the long-term outcome of the programmed treatment of classical Hodgkin's lymphoma (cHL) including high-dose chemotherapy (HDCT) and autologous hematopoietic stem cell transplantation (auto-HSCT) as well as the effect of various factors on the achieved results in a singlecenter study. Materials & Methods. In the A.A. Maksimov Clinical Center of Hematology and Cellular Therapy of the NI Pirogov Russian National Medical Center of Surgery 260 cHL patients received HDCT combined with auto-HSCT within the period from December 2006 to March 2017. The median age was 29 years (range 17-62). The study included 40 % men (п = 104), and 60 % women (п = 156). The median pretransplantation chemotherapy line was 3 (range 2-9). At this stage, prior to auto-HSCT, complete remission (CR) rate was 26.5 %, partial remission (PR) rate was 52.3 %, disease stabilisation rate was 13.5 %. HDCT with auto-HSCT was applied beyond progression as a salvage therapy in 7.7 % of patients. In 79.6 % of patients the standard BEAM and CBV conditioning regimens were used. Results. After HDCT combined with auto-HSCT overall 5-year survival (OS) of 260 cHL patients was 74 %, and 5-year progression-free survival (PFS) was 48 %, which corresponds to the results of some international studies. 5-year OS rates were significantly higher after HDCT and auto-HSCT performed during the first CR or PR (85 %) vs the second and subsequent CR and PR (71 %). Neither gender (p = 0.4) nor ECOG status (p = 0.2) effects on OS and PFS were revealed. 5-year OS rates were significantly higher after HDCT and auto-HSCT performed during CR or PR (82 %) vs disease stabilisation and progression (54 %) as well as upon achieving CR (93 %) vs PR (77 %). Conclusion. In cHL tumor sensitivity to chemotherapy is the essential indication for HDCT combined with auto-HSCT. The optimal time for HDCT and auto-HSCT in cHL is the first CR/PR, and the best treatment outcome is achieved in patients with complete response prior to HDCT and auto-HSCT.

show abstract

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018

Cited by 52 publications

References 46 publications

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma

Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin’s lymphoma involving the mediastinum

Outcome of Classical Hodgkin’s Lymphoma Treatment Based on HighDose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation: The Experience in the NI Pirogov Russian National Medical Center of Surgery

Contact Info

Product

Resources

About